Multiple Sclerosis (MS) Market Research Reports & Industry Analysis
The prevalence rate of MS in the United States is approximately 57.8 per 100,000. Above the 37th parallel, the prevalence is reported at 68.8 per 100,000, and below it, it is reported at 35.5 per 100,000 Scientists continue their extensive efforts to create new and better therapies for MS. One of the most promising MS research areas involves naturally occurring antiviral proteins known as interferons. Beta interferon has been shown to reduce the number of exacerbations and may slow the progression of physical disability.
When attacks do occur, they tend to be shorter and less severe. In addition, there are a number of treatments under investigation that may curtail attacks or improve function. Over a dozen clinical trials testing potential therapies are underway, and additional new treatments are being devised and tested in animal models. There are a variety of treatments for M.S. which are indicated to slow the progress of the disease.
Multiple Sclerosis (MS) Industry Research & Market Reports
-
Multiple sclerosis - Pipeline Insight, 2022
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered • Global coverage Multiple sclerosis ... Read More
-
Multiple Sclerosis - Epidemiology Forecast to 2032
... Sclerosis Disease Understanding Multiple sclerosis (MS) is the most common neurological disorder in young adults, with symptoms usually occurring between the ages of 20 and 40 years. Multiple Sclerosis attacks the axons of the central ... Read More
-
Global Neurorehabilitation Market Size study, by Type (Neuro-Robotic Devices, Non-Invasive Stimulators, and Brain-Computer Interfaces), by Application (Brain Stroke, Parkinson's Disease, Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury, Cerebral Palsy, and Others), by and End-User (Rehabilitation Centers, Hospitals, and Clinics) and Regional Forecasts 2021-2027
... (Rehabilitation Centers, Hospitals, and Clinics) and Regional Forecasts 2021-2027 Global Neurorehabilitation Market is valued at approximately USD 1097.69 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 8.3 ... Read More
-
Global Interferons Market Product Type (Interferon Alpha, Interferon Beta, Interferon Gamma), By Application (Hepatitis B, Hepatitis C, Melanoma, Leukemia, Multiple Sclerosis, Renal Cell Carcinoma), Regional Forecasts 2021-2027
... XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than 5.7% over the forecast period 2021-2027. The interferons are biopharmaceuticals made from live creatures like microbes and animal ... Read More
-
Targeted Therapeutics Market - By Type (Monoclonal Antibodies, Small Molecular Inhibitors, Prodrug, And Nano-Particulate Antibody Conjugates), By Application (Breast Cancer, Leukemia, Colorectal Cancer, Lymphoma, Renal Cancer, Multiple Sclerosis, Wet Age-Related Macular Degeneration, And Lung Cancer), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, And Retail Pharmacies),And By Region- Global Industry Perspective, Comprehensive Analysis, And Forecast, 2021 – 2030
... By Distribution Channel (Hospital Pharmacies, Online Pharmacies, And Retail Pharmacies),And By Region- Global Industry Perspective, Comprehensive Analysis, And Forecast, 2021 – 2030 Market Overview Fatpos Global has released a report titled Targeted Therapeutics Market - ... Read More
-
Primary Progressive Multiple Sclerosis (PPMS) - Epidemiology Forecast to 2032
... United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Primary ... Read More
-
Secondary Progressive Multiple Sclerosis (SPMS) - Epidemiology Forecast to 2032
... United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Secondary ... Read More
-
Chronic Progressive Multiple Sclerosis - Epidemiology Forecast to 2032
... EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Chronic Progressive Multiple ... Read More
-
Relapsing Multiple Sclerosis (RMS) - Epidemiology Forecast to 2032
... EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Geographies Covered • The United States • EU5 (Germany, France, Italy, Spain, and the United Kingdom) • Japan Study Period: 2019-2032 Relapsing Multiple Sclerosis ... Read More
-
Relapsing Multiple Sclerosis (RMS) - Market Insight, Epidemiology and Market Forecast -2032
... (RMS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Relapsing Multiple Sclerosis (RMS) market report provides current treatment practices, emerging drugs, Relapsing Multiple Sclerosis (RMS) market ... Read More
-
Walking impairment in Multiple sclerosis Market Insights, Competitive Landscape and Market Forecast–2026
... Multiple sclerosis and the historical and forecasted Walking impairment in Multiple sclerosis market trends, globally, which comprises of North America, Europe, APAC, and RoW. The Walking impairment in Multiple sclerosis market report provides an overview ... Read More
Research Assistance
